QS Investors’s Arcturus Therapeutics ARCT Stock Holding History

QS Investors’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-22,900	Closed	-$1.07M	–	1199
2020 Q2	$1.07M	Buy	+22,900	New	+$789K	0.01%	701

Other funds holding ARCT

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

QS Investors's ARCT Position: Q3 2020 in Review

QS Investors sold out of Arcturus Therapeutics (ARCT) in Q3 2020, closing a stake of 22,900 shares — an estimated $1.07M sold.

QS Investors first reported a position in ARCT in Q2 2020 and held it in 1 quarter. The position peaked at $1.07M in Q2 2020. 127 funds tracked by Wall St. Rank hold ARCT as of Q3 2020.

QS Investors reported no remaining Arcturus Therapeutics position as of Q3 2020 after selling out during the quarter.
QS Investors sold 22,900 Arcturus Therapeutics shares in Q3 2020, an estimated $1.07M.
QS Investors first reported a position in Arcturus Therapeutics in Q2 2020 and held it in 1 quarter.
QS Investors's Arcturus Therapeutics position peaked at $1.07M in Q2 2020.
127 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2020.

Based on QS Investors's 13F filing for Q3 2020, filed 12 Nov 2020.